Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Seliger

Showing results (281-290 of 304) with videos related to

Pageof 31
Sort By:
Cancer Research|November 13, 2003
Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remissionIlka B Schiffer, Susanne Gebhard, Carolin K Heimerdinger, et al.
Atherosclerosis|December 3, 2014
Interleukin-1 potently contributes to 25-hydroxycholesterol-induced synergistic cytokine production in smooth muscle cell-monocyte interactionsHang Fu, Florian Spieler, Julia Großmann, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.
Scientific Reports|February 9, 2020
"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cellsNicola Mitwasi, Anja Feldmann, Claudia Arndt, et al.
Journal for Immunotherapy of Cancer|June 28, 2017
Immunotherapy biomarkers 2016: overcoming the barriersJames L Gulley, Jay A Berzofsky, Marcus O Butler, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
Frontiers in Immunology|June 29, 2023
A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cellsAlexandra Kegler, Laura Drewitz, Claudia Arndt, et al.
Journal for Immunotherapy of Cancer|July 28, 2021
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancerAlexander Stein, Donjete Simnica, Christoph Schultheiß, et al.
Nature Communications|September 18, 2020
Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancerAitziber Buqué, Norma Bloy, Maria Perez-Lanzón, et al.
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 1 - Early Stage Breast CancerManfred Welslau, Volkmar Müller, Diana Lüftner, et al.
Pageof 31

Showing results (281-290 of 304) with videos related to

Sort By:
Pageof 31
Cancer Research|November 13, 2003
Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remissionIlka B Schiffer, Susanne Gebhard, Carolin K Heimerdinger, et al.
Atherosclerosis|December 3, 2014
Interleukin-1 potently contributes to 25-hydroxycholesterol-induced synergistic cytokine production in smooth muscle cell-monocyte interactionsHang Fu, Florian Spieler, Julia Großmann, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.
Scientific Reports|February 9, 2020
"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cellsNicola Mitwasi, Anja Feldmann, Claudia Arndt, et al.
Journal for Immunotherapy of Cancer|June 28, 2017
Immunotherapy biomarkers 2016: overcoming the barriersJames L Gulley, Jay A Berzofsky, Marcus O Butler, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
Frontiers in Immunology|June 29, 2023
A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cellsAlexandra Kegler, Laura Drewitz, Claudia Arndt, et al.
Journal for Immunotherapy of Cancer|July 28, 2021
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancerAlexander Stein, Donjete Simnica, Christoph Schultheiß, et al.
Nature Communications|September 18, 2020
Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancerAitziber Buqué, Norma Bloy, Maria Perez-Lanzón, et al.
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 1 - Early Stage Breast CancerManfred Welslau, Volkmar Müller, Diana Lüftner, et al.
Pageof 31